✦ LIBER ✦

GALNT11 as a new molecular marker in chronic lymphocytic leukemia

✍ Scribed by Libisch, M.G.; Casás, M.; Chiribao, ML.; Moreno, P.; Cayota, A.; Osinaga, E.; Oppezzo, P.; Robello, C.

Book ID: 121273399
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 465 KB
Volume: 533
Category: Article
ISSN: 0378-1119
DOI: 10.1016/j.gene.2013.09.052

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CD1d expression as a prognostic marker f

CD1d expression as a prognostic marker for chronic lymphocytic leukemia

✍ Anastasiadis, Athanasios; Kotsianidis, Ioannis; Papadopoulos, Vasileios; Spanoud 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 313 KB

RNA-based markers as prognostic factors

RNA-based markers as prognostic factors in chronic lymphocytic leukemia

✍ Sevov, Marie; Rosenquist, Richard; Mansouri, Larry 📂 Article 📅 2012 🏛 Expert Reviews 🌐 English ⚖ 850 KB

Reduced expression of CD20 antigen as a

Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia

✍ Nidal M. Almasri; Ricardo E. Duque; Jose Iturraspe; Eric Everett; Raul C. Brayla 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 461 KB

Small nucleolar RNAs as new biomarkers i

Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia

✍ Ronchetti, Domenica; Mosca, Laura; Cutrona, Giovanna; Tuana, Giacomo; Gentile, M 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 492 KB

Molecular bases of chronic lymphocytic l

Molecular bases of chronic lymphocytic leukemia in light of new treatments

✍ Rossi, Davide; Ciardullo, Carmela; Spina, Valeria; Gaidano, Gianluca 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 144 KB

[Advances in Experimental Medicine and B

[Advances in Experimental Medicine and Biology] Advances in Chronic Lymphocytic Leukemia Volume 792 || Molecular Biomarkers in Chronic Lymphocytic Leukemia

✍ Malek, Sami 📂 Article 📅 2013 🏛 Springer New York 🌐 English ⚖ 179 KB

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. CLL has a highly varied clinical course. While advances in CLL therapy are noted, many patients still succumb to this illness. Like most progress in medicine, solid advances in the diagnosis, prognosis and treatmen